ATS 2024 Final Program

Click on the session title to view the speakers

34

SUNDAY • MAYs 19

904 Dupilumab Improves Post-bronchodilator Lung Function in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial 905 Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial 906 In The Phase 3 Boreas Trial, Dupilumab Reduced FeNO Levels Over Time in Patients With Moderate-to-Severe COPD With Type 2 Inflammation 907 Efficacy of Mepolizumab in Patients With COPD and an Eosinophilic Phenotype With Chronic Bronchitis - A Post Hoc Analysis of the METREX & METREO Phase 3 Studies 908 Post Hoc Analysis of Quantitative HRCT Imaging Parameters in Astegolimab (anti-ST2) Treated COPD Patients Associates Airway Wall Thickness With Clinical Outcomes 909 Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Improved Dyspnea in Subjects With Symptomatic, Moderate-to-Severe COPD Over 24 Weeks 910 Ensifentrine Added on to LAMA Therapy Improved COPD Symptoms and Quality of Life in Subjects With Symptomatic Moderate-to-Severe COPD 911 Ensifentrine Added on to LABA/ICS Therapy Reduced Dyspnea and Improved Quality of Life in Subjects With Symptomatic Moderate-to-Severe COPD 912 Optimizing the Initiation of Inhaled Corticosteroids in COPD Management: An In-depth Exploration of Prescription Strategies and Clinical Outcomes Budesonide/Glycopyrrolate/Formoterol Fumarate on Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post-hoc Analysis of ETHOS Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) Versus Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) to Treat COPD Based on Mortality Risk Reduction Froma Matching-adjusted Indirect Treatment Comparison 913 Effect of Triple Inhaled Therapy With 914 Cost-effectiveness of

915 Alvelestat (MPH966) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATALANTa): A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of Alvelestat in Alpha-1 Antitrypsin Deficiency 916 Protease Inhibitory Specificity Profile of the Recombinant Human Alpha-1 Antitrypsin (AAT)-Fc Fusion Protein INBRX-101 917 Pharmacokinetics, Safety, and Tolerability of Tanimilast Following Single Administration in Subjects With Mild, Moderate, and Severe Renal Impairment 918 Pharmacokinetics, Safety, and Tolerability of Tanimilast Following Single Administrations in Subjects With Mild, Moderate, and Severe Hepatic Impairment 919 In Silico Lung Deposition Profiles of Three Single-inhaler Triple Therapy Combinations Assessed With Functional Respiratory Imaging (FRI) at a Low Inspiratory Flow Rate 920 Lung Exposure Bioequivalence With Budesonide/Glycopyrrolate/Formoterol Fumarate With the Next Generation Propellant Hydrofluoroolefin-1234ze Versus Hydrofluoroalkane-134a in Healthy Adults: A Charcoal Block Study 921 Utilizing Flow Profiles to Monitor and Improve pMDI Drug Delivery in Patients With COPD and Asthma 922 Bronchoscopic Lung Volume Reduction With Zephyr Endobronchial Valves Improves Lung Function and Symptoms in Chronic Obstructive Pulmonary Disease Patients With Alpha-1 Antitrypsin Deficiency 923 Bronchial Rheoplasty Reduces Mucus Plugging in Patients With Chronic Bronchitis 924 Phase III Two Arm, Multi-centre, Open Label, Parallel-group Randomised Designed Clinical Investigation of the Use of a Personalised Early Warning Decision Support System to Predict and Prevent Acute Exacerbations of Chronic Obstructive Pulmonary Disease: 925 Autologous Transplantation of P63+ Lung Progenitor Cells for Chronic Obstructive Pulmonary Disease Therapy: An Open-label, Controlled, First-in-Human Trial

ATS 2024 Conference Program • San Diego, CA